Stephane Budel
I track the market forces that turn -omics progress into clinical adoption –or prevent it from happening– and the long road from sick-care to healthcare. As founding partner at DeciBio, I have spent two decades advising the companies, investors, and executives building the tools and diagnostics layer of precision medicine.
"The precision medicine revolution will be driven by life science tools and diagnostics."
Thinking
For the rest of us in this industry we love dearly, it must be a command: act now, or watch the infrastructure behind tomorrow's cures erode. Tools and diagnostics save lives. It's time to pay and plan like they do.
Read essay →What's missing is a shared drive to fight for diagnostics to be seen, valued, and prioritized. And yes, even lobbied for. If we want to reduce healthcare costs and improve outcomes, we must invest (smartly and boldly) in diagnostics.
Read essay →From the field
Shorter observations from conferences, conversations, and moments of market clarity.
France isn't arguing about whether precision diagnostics matter anymore. The argument now is how to make them reimbursed, routine, and equitable — and that turns out to be a business-model question as much as a clinical one.
May 2026I left Roche Diagnostics Day with one overriding impression: this was not really a product launch event as much as a full diagnostics platform buildout. Roche is assembling the operating system for precision medicine.
April 2026Alamar's IPO is a signal that proteomics is becoming investable again — and that precision medicine is expanding beyond DNA. Genomics told us what could happen. Proteomics may tell us what is happening.
Public record
Articles, interviews, podcasts, and public appearances.
Episode 39 — how NGS is transforming cancer care through precision medicine, and what still stands in the way: insurance coverage gaps, clinical workflow friction, and the slow march from test availability to test adoption.
TPM Podcast #46 — liquid biopsy, multi-omics, and AI are reshaping personalized care, but the diagnostics business model still hinders the field. A conversation about what it will take to make these technologies accessible at scale.
A live(ish) conversation recorded at AGBT 2025 — covering the state of play in next-generation sequencing: where the market stands, what the conference signaled, and what comes next for the tools and diagnostics layer of genomics.
A conversation with Theral Timpson about how recent economic pressures have exposed fundamental flaws in the life science tools business model — and why the foundational pricing assumptions in the sector need to be rethought from the ground up.
About
Stephane Budel is a life sciences strategy advisor focused on tools, diagnostics, genomics, and precision medicine.
Founding partner at DeciBio. PhD from Yale. Writing about how technologies become markets, how diagnostics shape care, and why the infrastructure of precision medicine is undervalued.
More about Stephane →